Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024)
Historic FCF Margin for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to 225.05%.
- Amylyx Pharmaceuticals' FCF Margin fell 2354700.0% to 225.05% in Q4 2024 from the same period last year, while for Sep 2025 it was 589.12%, marking a year-over-year decrease of 5450100.0%. This contributed to the annual value of 146.86% for FY2024, which is 1493300.0% down from last year.
- According to the latest figures from Q4 2024, Amylyx Pharmaceuticals' FCF Margin is 225.05%, which was down 2354700.0% from 9988.22% recorded in Q3 2024.
- Amylyx Pharmaceuticals' FCF Margin's 5-year high stood at 10.42% during Q4 2023, with a 5-year trough of 9988.22% in Q3 2024.
- Over the past 4 years, Amylyx Pharmaceuticals' median FCF Margin value was 189.47% (recorded in 2022), while the average stood at 2931.59%.
- In the last 5 years, Amylyx Pharmaceuticals' FCF Margin soared by 79542900bps in 2023 and then tumbled by -99832800bps in 2024.
- Amylyx Pharmaceuticals' FCF Margin (Quarter) stood at 7374.74% in 2021, then soared by 97bps to 189.47% in 2022, then soared by 106bps to 10.42% in 2023, then crashed by -2259bps to 225.05% in 2024.
- Its FCF Margin stands at 225.05% for Q4 2024, versus 9988.22% for Q3 2024 and 6517.01% for Q2 2024.